ENTRY       D11470                      Drug
NAME        Imlifidase (USAN/INN);
            Idefirix (TN)
FORMULA     C1575H2400N422O477S6
EXACT_MASS  35049.484
MOL_WEIGHT  35070.8397
SEQUENCE    MDSFSANQEI RYSEVTPYHV TSVWTKGVTP PANFTQGEDV FHAPYVANQG WYDITKTFNG
            KDDLLCGAAT AGNMLHWWFD QNKDQIKRYL EEHPEKQKIN FNGEQMFDVK EAIDTKNHQL
            DSKLFEYFKE KAFPYLSTKH LGVFPDHVID MFINGYRLSL TNHGPTPVKE GSKDPRGGIF
            DAVFTRGDQS KLLTSRHDFK EKNLKEISDL IKKELTEGKA LGLSHTYANV RINHVINLWG
            ADFDSNGNLK AIYVTDSDSN ASIGMKKYFV GVNSAGKVAI SAKEIKEDNI GAQVLGLFTL
            STGQDSWNQT N
  TYPE      Peptide
REMARK      ATC code: L04AA41
EFFICACY    Immunosuppressant, Immunoglobulin modulator (enzyme)
COMMENT     Pre-transplant treatment to make patients with donor specific IgG eligible for kidney transplantation
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L04 IMMUNOSUPPRESSANTS
               L04A IMMUNOSUPPRESSANTS
                L04AA Selective immunosuppressants
                 L04AA41 Imlifidase
                  D11470  Imlifidase (USAN/INN)
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D11470
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11470
DBLINKS     CAS: 1947415-68-0
            PubChem: 384585446
///
